Dual Anti-HER2 Targeting in the Adjuvant ALTTO ph III Trial
Speaker: Giuseppe Curigliano
ALTTO Phase 3 trial results: First results comparing one year of anti-HER2 therapy with single therapy vs sequence or combination therapy in the adjuvant setting for HER2-positive early breast cancer.
- Brief summary of results
- Implications for clinical practice
- Specific warnings to practitioners
- Need for further research in the field